Trial reportAmerican journal of preventive medicine2025
Augmented Doses of Nicotine Replacement Therapy: Feasibility for Dual Cigarette and E-Cigarette Cessation.
Trial report in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06087328 (Comparing the Effects of Augmented Doses of Nicotine Replacement Therapy on Quitting Cigarettes and E-cigarettes), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparing the Effects of Augmented Doses of Nicotine Replacement Therapy on Quitting Cigarettes and E-cigarettes
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Interventions for quitting vaping.The Cochrane database of systematic reviews · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionDual use of combustible cigarettes and e-cigarettes is common and has harmful health effects. Many who dual use want to quit, but there are no empirically supported dual cessation interventions. High-dose nicotine replacement therapy is effective for treating heavy smoking and may be applied to treating dual use of combustible cigarettes and e-cigarettes.
methodsIn this pilot feasibility trial, individuals using both combustible cigarettes and e-cigarettes who wanted to quit were randomly assigned to a 28-day supply of nicotine replacement therapy in one of 3 doses: Standard (21mg patch, qd + 4mg lozenge prn [minimum of 5, up to 20/day]); Mid (21mg patch + 14mg patch + 4mg lozenge [5-30/day]), or High (2 × 21mg patches + 4mg lozenges [5-40/day]). Participants reported combustible cigarette and e-cigarette use daily throughout treatment and 1-month follow-up.
resultsParticipants enrolled in the study (N=46 from 2023 to 2024, analyzed 2025) had high nicotine dependence and most completed study procedures. Participants in the Mid group reported using nicotine replacement therapy on more days relative to the other groups. Participants in Mid and High reported numerically higher 7-day point-prevalence dual abstinence at end of treatment (13% for both groups vs 6% Standard) and follow-up (33% for both groups vs 0% Standard). Generaelized estimating equation models showed a significantly higher likelihood of abstinence on a given day for the Mid and High groups relative to Standard (ps<0.05).
conclusionsAugmented doses of nicotine replacement therapy are a feasible, promising treatment for dual cessation of combustible cigarettes and e-cigarettes. Future research should evaluate this approach in a more rigorous, fully powered trial.
trial registrationThis study is registered at www. CLINICALTRIALS: gov NCT06087328.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.